The IL-33/ST2 pathway: therapeutic target and novel biomarker. - Test2 - elhamkhani - TriplyDB

The IL-33/ST2 pathway: therapeutic target and novel biomarker.

The IL-33/ST2 pathway: therapeutic target and novel biomarker.

http://www.wikidata.org/entity/Q34776884

about

Evolutionary divergence and functions of the human interleukin (IL) gene family High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1 The Dynamic Role of the IL-33/ST2 Axis in Chronic Viral-infections: Alarming and Adjuvanting the Immune Response Interleukin-33 and Mast Cells Bridge Innate and Adaptive Immunity: From the Allergologist's Perspective Transcriptomic biomarkers of cardiovascular disease Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry ST2 and IL-33 in pregnancy and pre-eclampsia Cross-species evidence for the role of interleukin-33 in depression risk Cellular mechanisms of tissue fibrosis. 6. Purinergic signaling and response in fibroblasts and tissue fibrosis Intramyocardial fibroblast myocyte communication.IL-33 promotes DC development in BM culture by triggering GM-CSF production Effects of interleukin-33 on cardiac fibroblast gene expression and activity.IL-33/ST2-mediated inflammation in macrophages is directly abrogated by IL-10 during rheumatoid arthritis.A functional variant in ST2 gene is associated with risk of hypertension via interfering MiR-202-3p.IL-33 shifts macrophage polarization, promoting resistance against Pseudomonas aeruginosa keratitis.Role of IL-33 and its receptor in T cell-mediated autoimmune diseases Interleukin 33: a switch-hitting cytokine.Type I IL-1 receptor (IL-1RI) as potential new therapeutic target for bronchial asthma.Caspase-1: an integral regulator of innate immunity.Plasma levels of soluble interleukin 1 receptor accessory protein are reduced in obesity.Expression of IL-33 and its epigenetic regulation in Multiple Sclerosis.Soluble ST2, a modulator of the inflammatory response, in preterm and term labor IL1RL1 gene variants and nasopharyngeal IL1RL-a levels are associated with severe RSV bronchiolitis: a multicenter cohort study.Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts.Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure [Caspase-1 regulates autoinflammation in rheumatic diseases].Cliques for the identification of gene signatures for colorectal cancer across population.Disordered IL-33/ST2 activation in decidualizing stromal cells prolongs uterine receptivity in women with recurrent pregnancy loss.Modification of hemodynamic and immune responses to exposure with a weak antigen by the expression of a hypomorphic BMPR2 gene Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells.IL-33 attenuates anoxia/reoxygenation-induced cardiomyocyte apoptosis by inhibition of PKCβ/JNK pathway.Emerging biomarkers in heart failure and cardiac cachexia Amplification of cytokine production through synergistic activation of NFAT and AP-1 following stimulation of mast cells with antigen and IL-33 SIRT1 deficiency in microglia contributes to cognitive decline in aging and neurodegeneration via epigenetic regulation of IL-1β.The anti-atherogenic cytokine interleukin-33 inhibits the expression of a disintegrin and metalloproteinase with thrombospondin motifs-1, -4 and -5 in human macrophages: Requirement of extracellular signal-regulated kinase, c-Jun N-terminal kinase a Targeting ST2L potentiates CpG-mediated therapeutic effects in a chronic fungal asthma model.Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome

P2860

Q21245454-95C0F36A-CAB8-46F7-BCDB-4D5C9ED7A8F4 Q24610732-D7CD04CE-3EE4-4D39-A0AD-CAA894686811 Q24649639-CF412CB0-43A8-4479-BB93-D83C516B01DA Q24651453-E8A4B10B-F1D5-4D60-9851-9B2AF3791C5B Q26743383-D7FA701F-B22F-4BE9-9650-679E434E0969 Q26775911-F7ADBB88-1673-4232-99AB-E5F8FB51E19A Q27001652-B25099FF-D0D1-478B-9684-EA3341CD3354 Q28253329-072442E4-4337-4932-8BED-7ECDF6F27482 Q28395328-B4385E0A-6A9C-4420-9992-7FB28E45E2B1 Q28740320-0C852EBD-F8C3-467E-BA69-39B82FA8EB13 Q30749968-33CC6C39-0AAD-4557-A871-CFE5341F3DC4 Q33569405-40B19A3A-DA3E-4D64-9EFF-AE73AE407758 Q33586605-52DDD54E-B896-405F-AC83-CC45D09440EA Q33719228-813DF2C8-33A4-494F-B36D-4D33881FA881 Q33765909-12E563A7-32F5-4B2E-B775-D83912CAE6D2 Q33779103-3DD91184-8FCF-4B67-9D40-719130DA1002 Q33844678-981CC48B-5944-4677-A4EA-D08EE8ACDEC3 Q33845161-00179100-AFE2-49F9-9A94-238109CD5490 Q33854499-78F6E78E-9345-4E95-B4FD-1C831C1DDA4F Q33987547-59A4378A-B61F-4C76-8B50-3B9137106C66 Q34021990-BEF1C2EC-79EF-4DC0-AA4C-3275A03823E3 Q34044187-C4A82DC2-3256-4041-ABBA-C96726B41B59 Q34130963-9A8F5ABD-E15A-4FA7-9C71-9D43C77F002F Q34149191-7585E934-FD3E-473D-BA86-28F24E591B88 Q34164039-098579F6-2ABF-4628-A242-788889AB7983 Q34264474-6C0CCBBA-F2F7-4DE8-B0BC-391E28D70E49 Q34358060-EA33F508-8372-4A26-8395-FCE92A379B15 Q34472413-D520E5A0-339C-4424-9011-0A4A855AA002 Q34520488-C3859EF6-94CF-4C35-89E1-181F43AFA88D Q34530234-4A91660C-2435-4E12-BFE6-D8D3124C593E Q34540500-A3DF8C08-07D2-4820-B836-3D5C40233938 Q34576173-121B102B-B256-4ED4-8041-41E5EFE3C807 Q34577734-88274787-49EF-4C53-8652-F4C55539A109 Q34606519-14CF5A41-9344-443E-BCF8-52682339D562 Q34836097-C61E3330-E0B9-4B1C-9167-43B03C8DC402 Q34895161-43F8830B-1AFE-4DFD-BE83-8815377E0D88 Q34946464-08918C88-49BC-497A-AE13-7BC36F31794A Q35052649-C741AB22-6605-4643-850C-F1F47CDAA1A1 Q35070119-5F22402D-59A9-4C07-96FD-6AE5B89A125F Q35153947-DD3F9CB1-E59C-4B02-B5DD-CF7CE594EA1B

P2860

The IL-33/ST2 pathway: therapeutic target and novel biomarker.

http://www.wikidata.org/entity/Q34776884

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

The IL-33/ST2 pathway: therapeutic target and novel biomarker.

@ast

The IL-33/ST2 pathway: therapeutic target and novel biomarker.

@en

The IL-33/ST2 pathway: therapeutic target and novel biomarker.

@nl

type

label

The IL-33/ST2 pathway: therapeutic target and novel biomarker.

@ast

The IL-33/ST2 pathway: therapeutic target and novel biomarker.

@en

The IL-33/ST2 pathway: therapeutic target and novel biomarker.

@nl

prefLabel

The IL-33/ST2 pathway: therapeutic target and novel biomarker.

@ast

The IL-33/ST2 pathway: therapeutic target and novel biomarker.

@en

The IL-33/ST2 pathway: therapeutic target and novel biomarker.

@nl

P1433

Q34776884-797AEE4B-BA37-4E8A-B94A-91116AB95375

P1476

Q34776884-120FBD70-CF88-46F2-A6E8-0D53CA8CFB33

P2093

Q34776884-865EC37F-E8ED-41C2-8478-3198C058D0FC

Q34776884-BDF1B8D2-175C-4CFE-9038-463C03F30FA5

P2860

Q34776884-004BE45F-6C35-4B7F-879D-5E7E4FA551C0

Q34776884-013857E7-11AC-4C09-9B80-15FB718BD3BD

Q34776884-029A573E-3989-458C-AAD8-9C3F7B47914E

Q34776884-04AF705F-BDD6-47B2-A0CD-EC25E1450454

Q34776884-04EF39D9-E2F1-45CF-B0EA-9750BE291393

Q34776884-05203DF3-B4D9-41EF-B5F9-F195BE9F6DED

Q34776884-07D15578-6BC5-40AD-8D36-69603FEA37B2

Q34776884-0859D3A0-5BC5-4B35-B09A-8F6CDE2B5790

Q34776884-09B2CFEB-8105-4ACD-8D99-61A8E958AA31

Q34776884-0D6C784E-CAB9-474D-B56B-293D49FE0260

P2888

Q34776884-257533A3-EBB4-4E28-A770-F5A38CB357AE

P304

Q34776884-E34ED7B0-A31C-4E92-AB7F-CC6B8F85BB02

P31

Q34776884-2BC6800F-6FCD-414F-AD79-7D412ED306C2

P356

Q34776884-FDAB79B9-D5AE-4506-B0EA-7CCC6B1658B3

P433

Q34776884-96E9501A-0D2F-4727-AE1F-F1F7F14C30E3

P478

Q34776884-1804E71F-A911-4770-98A4-E937A2791C9F

P577

Q34776884-9DF1898C-4302-45D9-8A7F-9C446F114F9A

P698

Q34776884-F33F246A-914A-410A-A5EC-EC98B3DDBC1F

P921

Q34776884-D1B3D7CC-22AE-45E7-8B0C-9CA86A09F8EB

P932

Q34776884-63395AEC-BC25-4FF5-9E95-CDCE2DEC7114

P356

P1433

Nature Reviews Drug Discovery

P1476

The IL-33/ST2 pathway: therapeutic target and novel biomarker.

@en

P2093

Rahul Kakkar

http://www.w3.org/2001/XMLSchema#string

Richard T Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin-1 receptor cluster: gene organization of IL1R2, IL1R1, IL1RL2 (IL-1Rrp2), IL1RL1 (T1/ST2), and IL18R1 (IL-1Rrp) on human chromosome 2q

Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM

TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation : An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

The TIMI Risk Score for Unstable Angina/Non–ST Elevation MI

Structural basis for signal transduction by the Toll/interleukin-1 receptor domains

IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines

Active caspase-1 is a regulator of unconventional protein secretion

Crystallographic refinement of interleukin 1 beta at 2.0 A resolution

A novel IL-1 family cytokine, IL-33, potently activates human eosinophils

P2888

P304

827-840

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRD2660

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18827826

http://www.w3.org/2001/XMLSchema#string

P921

P932

4277436

http://www.w3.org/2001/XMLSchema#string